Abemaciclib

About

Therapy type: Targeted therapy

Therapy strategy: CDK4/6 inhibition

Mappings

NCI Thesaurus: Abemaciclib (ncit:C97660)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HC